Daniel Wisehart is an associate at Wach + Meckes LLP, Munich. He has previously worked as a researcher at the Universität Potsdam and the Universität Freiburg and clerked for the European Court of Human Rights.

Select Guide Rating

• Acknowledgments List of abbreviations1 Introduction1.1 International drug control after UNGASS 2016: more of the same or towards a fundamental turning point? 1.2 Objectives and methodology of this book2 The sources and actors of the international drug control system2.1 The primary sources of the international drug control system2.2 The institutions of the international drug control system and a typology of their secondary instruments2.3 Conclusion3 The emergence of the international drug control system3.1 Towards one coherent obligation to confine drugs to medical and scientific purposes3.2 A constant expansion of the international drug control system3.3 The international drug control system as a prime example of the law of cooperation3.4 Conclusion4 The objective of the international drug control system: limitation of drugs to medical and scientific purposes4.1 The need to understand the limitation of drugs to medical and scientific purposes4.2 The meaning of the limitation of all drug-related activities to medical and scientific purposes 4.3 Exceptions to the limitation of drugs to medical and scientific purposes within the international drug control system4.4 Options to deviate from the limitation of drugs to medical and scientific purposes in the international drug control system4.5 Does international human rights law conflict with the limitation of drugs to medical and scientific purposes?4.6 Conclusion5 The material scope of the international drug control system5.1 Substances limited to medical and scientific purposes5.2 Modification of the scope of application of the international drug control system (scheduling) 5.3 Prospects for exempting cannabis and the coca leaf from drug control’s scope of application 5.4 The challenge of regulating uncertainty: the rise of new psychoactive substances and the international drug control system 5.5 Conclusion6 Challenges to the implementation of the international drug control system6.1 Control of the licit supply chain: achieving a balance between limiting and ensuring an adequate availability of drug supply?6.2 Suppression of illicit supply: the UN Drug Conventions as a punitive and sanction-oriented system of control?6.3 Demand-reduction obligations providing for a human- and health-oriented treatment of drug users?6.4 Fairness and the premise of the international drug control system to limit drugs to medical and scientific purposes by relying on a control of drug supply6.5 Conclusion7 Concluding remarks and outlookBibliographyIndex

Daniel Wisehart is an associate at Wach + Meckes LLP, Munich. He has previously worked as a researcher at the Universität Potsdam and the Universität Freiburg and clerked for the European Court of Human Rights.

Select Guide Rating

• Acknowledgments List of abbreviations1 Introduction1.1 International drug control after UNGASS 2016: more of the same or towards a fundamental turning point? 1.2 Objectives and methodology of this book2 The sources and actors of the international drug control system2.1 The primary sources of the international drug control system2.2 The institutions of the international drug control system and a typology of their secondary instruments2.3 Conclusion3 The emergence of the international drug control system3.1 Towards one coherent obligation to confine drugs to medical and scientific purposes3.2 A constant expansion of the international drug control system3.3 The international drug control system as a prime example of the law of cooperation3.4 Conclusion4 The objective of the international drug control system: limitation of drugs to medical and scientific purposes4.1 The need to understand the limitation of drugs to medical and scientific purposes4.2 The meaning of the limitation of all drug-related activities to medical and scientific purposes 4.3 Exceptions to the limitation of drugs to medical and scientific purposes within the international drug control system4.4 Options to deviate from the limitation of drugs to medical and scientific purposes in the international drug control system4.5 Does international human rights law conflict with the limitation of drugs to medical and scientific purposes?4.6 Conclusion5 The material scope of the international drug control system5.1 Substances limited to medical and scientific purposes5.2 Modification of the scope of application of the international drug control system (scheduling) 5.3 Prospects for exempting cannabis and the coca leaf from drug control’s scope of application 5.4 The challenge of regulating uncertainty: the rise of new psychoactive substances and the international drug control system 5.5 Conclusion6 Challenges to the implementation of the international drug control system6.1 Control of the licit supply chain: achieving a balance between limiting and ensuring an adequate availability of drug supply?6.2 Suppression of illicit supply: the UN Drug Conventions as a punitive and sanction-oriented system of control?6.3 Demand-reduction obligations providing for a human- and health-oriented treatment of drug users?6.4 Fairness and the premise of the international drug control system to limit drugs to medical and scientific purposes by relying on a control of drug supply6.5 Conclusion7 Concluding remarks and outlookBibliographyIndex

Daniel Wisehart is an associate at Wach + Meckes LLP, Munich. He has previously worked as a researcher at the Universität Potsdam and the Universität Freiburg and clerked for the European Court of Human Rights.

Select Guide Rating

• Acknowledgments List of abbreviations1 Introduction1.1 International drug control after UNGASS 2016: more of the same or towards a fundamental turning point? 1.2 Objectives and methodology of this book2 The sources and actors of the international drug control system2.1 The primary sources of the international drug control system2.2 The institutions of the international drug control system and a typology of their secondary instruments2.3 Conclusion3 The emergence of the international drug control system3.1 Towards one coherent obligation to confine drugs to medical and scientific purposes3.2 A constant expansion of the international drug control system3.3 The international drug control system as a prime example of the law of cooperation3.4 Conclusion4 The objective of the international drug control system: limitation of drugs to medical and scientific purposes4.1 The need to understand the limitation of drugs to medical and scientific purposes4.2 The meaning of the limitation of all drug-related activities to medical and scientific purposes 4.3 Exceptions to the limitation of drugs to medical and scientific purposes within the international drug control system4.4 Options to deviate from the limitation of drugs to medical and scientific purposes in the international drug control system4.5 Does international human rights law conflict with the limitation of drugs to medical and scientific purposes?4.6 Conclusion5 The material scope of the international drug control system5.1 Substances limited to medical and scientific purposes5.2 Modification of the scope of application of the international drug control system (scheduling) 5.3 Prospects for exempting cannabis and the coca leaf from drug control’s scope of application 5.4 The challenge of regulating uncertainty: the rise of new psychoactive substances and the international drug control system 5.5 Conclusion6 Challenges to the implementation of the international drug control system6.1 Control of the licit supply chain: achieving a balance between limiting and ensuring an adequate availability of drug supply?6.2 Suppression of illicit supply: the UN Drug Conventions as a punitive and sanction-oriented system of control?6.3 Demand-reduction obligations providing for a human- and health-oriented treatment of drug users?6.4 Fairness and the premise of the international drug control system to limit drugs to medical and scientific purposes by relying on a control of drug supply6.5 Conclusion7 Concluding remarks and outlookBibliographyIndex